Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Novartis AG — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $37.48 (market cap $3.56B), while Novartis AG trades at $142.97 (market cap $268.57B). The key difference: Novartis AG is far larger — about 75.4× GraniteShares 2x Long NVDA Daily ETF's market cap, and Novartis AG pays a 3.31% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Novartis AG for 82 Days on average.
| NVDL | NVS | |
|---|---|---|
Market Cap | $3.56B | $268.57B |
Volume | 9,740,643 | 1,532,573 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $168.62 |
52-Week Low | $21.76 | $121.80 |
Typical Hold Time | 15 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $37.335, down 5.65% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. Recent news highlights Nvidia's continued AI leadership and earnings beats, driving leveraged ETF interest. The ETF aims to deliver 2x daily returns of Nvidia stock, with technical analysis showing support at $36 and resistance at $38-39 levels.
The outlook remains tied to Nvidia's AI dominance and earnings performance. Investment opportunity exists through leveraged exposure to Nvidia's growth trajectory, though risks include daily reset leverage decay and Nvidia's high valuation. Recent SpaceX earnings have reshuffled AI chip trades, creating volatility. The ETF's performance depends on Nvidia maintaining its AI market leadership and execution.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
